These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32188777)

  • 1. β-Arrestin2 arrests the clearance of tau in FTLD.
    Thathiah A
    Proc Natl Acad Sci U S A; 2020 Mar; 117(13):6968-6970. PubMed ID: 32188777
    [No Abstract]   [Full Text] [Related]  

  • 2. β-Arrestin2 oligomers impair the clearance of pathological tau and increase tau aggregates.
    Woo JA; Liu T; Fang CC; Castaño MA; Kee T; Yrigoin K; Yan Y; Cazzaro S; Matlack J; Wang X; Zhao X; Kang DE; Liggett SB
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):5006-5015. PubMed ID: 32071246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration.
    Goossens J; Bjerke M; Van Mossevelde S; Van den Bossche T; Goeman J; De Vil B; Sieben A; Martin JJ; Cras P; De Deyn PP; Van Broeckhoven C; van der Zee J; Engelborghs S
    Alzheimers Res Ther; 2018 Mar; 10(1):31. PubMed ID: 29559004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD.
    Alcolea D; Irwin DJ; Illán-Gala I; Muñoz L; Clarimón J; McMillan CT; Fortea J; Blesa R; Lee EB; Trojanowski JQ; Grossman M; Lleó A
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):180-186. PubMed ID: 30297518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
    Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frontotemporal lobar degeneration: diversity of FTLD lesions.
    Seilhean D; Bielle F; Plu I; Duyckaerts C
    Rev Neurol (Paris); 2013 Oct; 169(10):786-92. PubMed ID: 24035575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Alzheimer's disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau).
    Gibbons GS; Kim SJ; Robinson JL; Changolkar L; Irwin DJ; Shaw LM; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2019 Mar; 7(1):34. PubMed ID: 30832741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid tau in frontotemporal lobar degeneration: clinical, neuroimaging, and prognostic correlates.
    Borroni B; Cerini C; Archetti S; Premi E; Cosseddu M; Ferrari M; Bellelli G; Gasparotti R; Caimi L; Di Luca M; Padovani A
    J Alzheimers Dis; 2011; 23(3):505-12. PubMed ID: 21098973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation.
    Papegaey A; Eddarkaoui S; Deramecourt V; Fernandez-Gomez FJ; Pantano P; Obriot H; Machala C; Anquetil V; Camuzat A; Brice A; Maurage CA; Le Ber I; Duyckaerts C; Buée L; Sergeant N; Buée-Scherrer V
    Acta Neuropathol Commun; 2016 Jul; 4(1):74. PubMed ID: 27435172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
    Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P
    J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontotemporal Lobar Degeneration.
    Premi E; Padovani A; Borroni B
    Adv Exp Med Biol; 2012; 724():114-27. PubMed ID: 22411238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into biological markers of frontotemporal lobar degeneration spectrum.
    Borroni B; Alberici A; Archetti S; Magnani E; Di Luca M; Padovani A
    Curr Med Chem; 2010; 17(10):1002-9. PubMed ID: 20156164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal dementia.
    Borroni B; Benussi A; Archetti S; Galimberti D; Parnetti L; Nacmias B; Sorbi S; Scarpini E; Padovani A
    Amyotroph Lateral Scler Frontotemporal Degener; 2015 Mar; 16(1-2):86-91. PubMed ID: 25352065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration.
    Irwin DJ; Lleó A; Xie SX; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    Ann Neurol; 2017 Aug; 82(2):247-258. PubMed ID: 28719018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
    Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
    J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration.
    van Eersel J; Stevens CH; Przybyla M; Gladbach A; Stefanoska K; Chan CK; Ong WY; Hodges JR; Sutherland GT; Kril JJ; Abramowski D; Staufenbiel M; Halliday GM; Ittner LM
    Neuropathol Appl Neurobiol; 2015 Dec; 41(7):906-25. PubMed ID: 25763777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pathology in primary progressive language and speech disorders.
    Deramecourt V; Lebert F; Debachy B; Mackowiak-Cordoliani MA; Bombois S; Kerdraon O; Buée L; Maurage CA; Pasquier F
    Neurology; 2010 Jan; 74(1):42-9. PubMed ID: 19940270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.